×

NeoStem and PCT, A NeoStem Company, to Present at Multiple December Conferences

NEW YORK, Dec. 1, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell based therapies, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in December.

Key Opinion Leader Webcast

  • Date and Time: Monday, December 1, 2014, 4:30 PM EST
  • Website: http://www.neostem.com/investors/investor-events/
  • Phone access: 1-855-235-8282, Conference ID 40994522
  • Presenter: Dr.Timothy Henry, Director of Cardiology, Cedars-Sinai Heart Institute
  • Topic: Phase 2 PreSERVE AMI initial clinical trial results

Piper Jaffray 26th Annual Healthcare Conference

  • Date and Time: Wednesday, December 3, 2014, 2:30 PM EST
  • Venue: New York Palace Hotel, New York, New York
  • Website: http://www.piperjaffray.com/2col.aspx?id=365
  • Presenter: Dr. Robin Smith, Chairman and Chief Executive Officer, NeoStem; and Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Company Presentation

2014 VIC Congress: Development and Manufacturing of Vaccines

  • Date and Time: Thursday, December 4, 2014, 8:30 AM CET
  • Venue: Sheraton Brussels Hotel, Brussels, Belgium
  • Website: http://www.informa-ls.com/event/Vaccines2014
  • Presenter: Dr. Cenk Sumen, Manager, Technology and Business Development, PCT
  • Topic: Efficient Manufacturing Strategies for T Cell Therapy

Oppenheimer 25th Annual Healthcare Conference

Commercialization of Cell, Gene & Immunotherapies

  • Date and Time: Friday, December 12, 2014, 2:30 PM PST
  • Venue: Andaz San Diego, San Diego, California
  • Website: http://www.ibclifesciences.com/CGITech/overview.xml
  • Presenter: Dr. Ian Gaudet, Senior Engineer, PCT
  • Topic: New Automated Cell Washing Device Using Spinning Membrane Filtration and Enabling Closed-System Processing

About NeoStem, Inc.

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

About PCT

Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc., is a leading contract development and manufacturing organization in the cellular therapy industry. For over 15 years, PCT has provided pre-clinical and clinical cGMP development and manufacturing services to more than 100 clients, advancing regenerative medicine product candidates from the development stage all the way through to human testing. PCT has two cGMP-compliant, state-of-the art facilities in New Jersey and California to serve the cell therapy industry and offers manufacturing of cell therapy-based products, engineering and innovation services, process and product development, cell and tissue processing, collection and storage, regulatory consulting, facility design, validation, and due diligence evaluations. www.pctcelltherapy.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, Ischemic Repair Program (including NBS10 for AMI), Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.

CONTACT: Investor Contact: LifeSci Advisors, LLC Hans Vitzthum Managing Director Phone: +1-212-915-2568 Email: hans@lifesciadvisors.com Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email: epowers@neostem.com

Source:NeoStem Inc.